Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

Malaysia Urged to Consider Approval of New Dengue Vaccine

The Health Ministry of Malaysia is urged to consider approving a newly released dengue vaccine to combat the increasing number of cases in the country, according to Datuk Dr Lam Sai Kit, a virologist and Universiti Malaya emeritus professor.

Dr. Lam highlighted the effectiveness of the Takeda dengue vaccine, known as Qdenga (TAK-003), which has been approved for use on individuals who have had dengue. Despite the implementation of an integrated vector control program and the use of Wolbachia-carrying Aedes mosquitoes in hotspots in the Klang Valley, the number of dengue cases has not significantly declined.

He emphasized the safety of Qdenga, stating that it has been generally well tolerated with no significant safety risks identified. The vaccine has received approval for licensing in the European Union (EU) and is currently available for children and adults in several countries, including the EU, United Kingdom, Indonesia, Thailand, and Brazil. Additionally, the World Health Organization (WHO) Strategic Advisory Group of Experts (Sage) recommended the Qdenga dengue tetravalent live attenuated vaccine for introduction to children aged six to 16 years.

Dr. Lam urged the Health Ministry to expedite the licensing of the Qdenga vaccine, ensuring that individuals who wish to be vaccinated have immediate access to it.

Dengue is a viral infection transmitted to humans through infected mosquito bites, causing a range of symptoms from asymptomatic to severe, including high fever, severe headache, acute joint and muscle pain, and in rare cases, internal bleeding, shock, and death. While there is no specific treatment for dengue, early detection and access to medical care can lower its fatality rate to below 1%.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *